Company intelligence / Profile preview

Bod Science

Australia

Ownership: Private
Development stage: Other

Overview

Bod Science has completed the pharmacokinetic (PK) analysis of the Aqua Phase platform showing a 311% increase in CBD bioavailability versus traditional CBD formulations. Results from ongoing insomnia trials are anticipated as a key milestone for broader commercial uptake and regulatory (TGA) approval

Therapeutic areas: NeurologyPsychiatryOther
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

DSM-Firmenich (for innovative cannabidiol formulations)

Beyond the preview

Go deeper on Bod Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bod Science.

Explore the full profile